South Africa to host WHO's first COVID-19 mRNA vaccine tech transfer hub

22 June 2021
south_africa_cape_town_shutterstock_large

The World Health Organization (WHO) and its COVAX partners are working with a South African consortium to establish the first COVID-19 mRNA vaccine technology transfer hub in the country.

This consortium comprises Cape Town-based companies Biovac and Afrigen Biologics and Vaccines, along with a network of universities and the Africa Centers for Disease Control and Prevention (CDC).

The move follows WHO’s global call for Expression of Interest (EOI) in April to establish COVID-19 mRNA vaccine technology transfer hubs to scale up production and access.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Today's issue

Company Spotlight





More Features in Biotechnology